Literature DB >> 32926648

Futility stopping in clinical trials, optimality and practical considerations.

Yen Chang1, Tianhao Song1, Jane Monaco1, Anastasia Ivanova1.   

Abstract

Stopping for futility is a useful tool in a clinical trial. It is widely used in single-arm trials in oncology and in many two-arm trials. We review three stopping rules for futility. We give recommendations for the optimal timing of futility looks in two-stage trials in terms of the information fraction and the probability of stopping under the alternative hypothesis. We discuss futility stopping in trials with substantial uncertainty about the variability of the outcome and in crossover trials.

Entities:  

Keywords:  Simon’s design; crossover trial; futility stopping; phase 2 trial

Mesh:

Year:  2020        PMID: 32926648      PMCID: PMC7954786          DOI: 10.1080/10543406.2020.1818253

Source DB:  PubMed          Journal:  J Biopharm Stat        ISSN: 1054-3406            Impact factor:   1.051


  13 in total

1.  Admissible two-stage designs for phase II cancer clinical trials that incorporate the expected sample size under the alternative hypothesis.

Authors:  Adrian P Mander; James M S Wason; Michael J Sweeting; Simon G Thompson
Journal:  Pharm Stat       Date:  2012-01-10       Impact factor: 1.894

2.  Assessment of futility in clinical trials.

Authors:  Steven Snapinn; Mon-Gy Chen; Qi Jiang; Tony Koutsoukos
Journal:  Pharm Stat       Date:  2006 Oct-Dec       Impact factor: 1.894

3.  Optimal two-stage designs for phase II clinical trials.

Authors:  R Simon
Journal:  Control Clin Trials       Date:  1989-03

4.  The B-value: a tool for monitoring data.

Authors:  K K Lan; J Wittes
Journal:  Biometrics       Date:  1988-06       Impact factor: 2.571

5.  Designs for group sequential tests.

Authors:  T R Fleming; D P Harrington; P C O'Brien
Journal:  Control Clin Trials       Date:  1984-12

6.  Alertness and psychomotor performance effects of the histamine-3 inverse agonist MK-0249 in obstructive sleep apnea patients on continuous positive airway pressure therapy with excessive daytime sleepiness: a randomized adaptive crossover study.

Authors:  W Joseph Herring; Kenneth Liu; Jill Hutzelmann; Duane Snavely; Ellen Snyder; Paulette Ceesay; Christopher Lines; David Michelson; Thomas Roth
Journal:  Sleep Med       Date:  2013-08-03       Impact factor: 3.492

Review 7.  Nine-year change in statistical design, profile, and success rates of Phase II oncology trials.

Authors:  Anastasia Ivanova; Barry Paul; Olga Marchenko; Guochen Song; Neerali Patel; Stergios J Moschos
Journal:  J Biopharm Stat       Date:  2016       Impact factor: 1.051

8.  Admissible two-stage designs for phase II cancer clinical trials.

Authors:  Sin-Ho Jung; Taiyeong Lee; KyungMann Kim; Stephen L George
Journal:  Stat Med       Date:  2004-02-28       Impact factor: 2.373

9.  An adaptive design for identifying the dose with the best efficacy/tolerability profile with application to a crossover dose-finding study.

Authors:  Anastasia Ivanova; Ken Liu; Ellen Snyder; Duane Snavely
Journal:  Stat Med       Date:  2009-10-30       Impact factor: 2.373

10.  Two-stage designs optimal under the alternative hypothesis for phase II cancer clinical trials.

Authors:  A P Mander; S G Thompson
Journal:  Contemp Clin Trials       Date:  2010-08-01       Impact factor: 2.226

View more
  2 in total

1.  Feasibility of Randomized Controlled Trials for Cancer Drugs Approved by the Food and Drug Administration Based on Single-Arm Studies.

Authors:  Rebekah Rittberg; Piotr Czaykowski; Saroj Niraula
Journal:  JNCI Cancer Spectr       Date:  2021-06-30

2.  The precision interventions for severe and/or exacerbation-prone asthma (PrecISE) adaptive platform trial: statistical considerations.

Authors:  Anastasia Ivanova; Elliot Israel; Lisa M LaVange; Michael C Peters; Loren C Denlinger; Wendy C Moore; Leonard B Bacharier; M Alison Marquis; Nathan M Gotman; Michael R Kosorok; Chalmer Tomlinson; David T Mauger; Steve N Georas; Rosalind J Wright; Patricia Noel; Gary L Rosner; Praveen Akuthota; Dean Billheimer; Eugene R Bleecker; Juan Carlos Cardet; Mario Castro; Emily A DiMango; Serpil C Erzurum; John V Fahy; Merritt L Fajt; Benjamin M Gaston; Fernando Holguin; Sonia Jain; Nicholas J Kenyon; Jerry A Krishnan; Monica Kraft; Rajesh Kumar; Mark C Liu; Ngoc P Ly; James N Moy; Wanda Phipatanakul; Kristie Ross; Lewis J Smith; Stanley J Szefler; W Gerald Teague; Michael E Wechsler; Sally E Wenzel; Steven R White
Journal:  J Biopharm Stat       Date:  2020-09-17       Impact factor: 1.051

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.